Just a moment, the page is loading...

Effectiveness of anti HER2 blockade according to host immune status

Effectiveness of anti HER2 blockade according to host immune status

Joon Jeong

Gangnam Severance HospitalDepartment of Surgery

28 Mar 2019

There are reports that immune related markers such as tumor infiltrating lymphocytes (TILs) are associated with treatment outcome and survival in HER2 positive breast cancer. However, these immune related markers can get through more complex and expensive tests. In our preliminary study, we identified a possibility of pre-treatment neutrophil to lymphocyte ratio (NLR) to guide neoadjuvant HER2 target therapy in HER2 positive early breast cancer. In addition, neutrohpil, lymphocyte count and neutrophil to lymphocyte ratio (NLR), which represents host immune status, have the advantage of being easily obtained with a simple blood test. The aim of the current study was to examine the role of host immune factors including neutrophil, lymphocytes, and NLR as a predictive and prognostic values in HER2 positive breast cancer patients. Also, we will validate our results with data from ‘clinicalstudydatarequest.

[{ "PostingID": 1340, "Title": "ROCHE-WO20698 (CLEOPATRA)", "Description": "A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Herceptin + docetaxel + pertuzumab versus Herceptin + docetaxel + placebo in previously untreated HER2-positive metastatic breast cancer" },{ "PostingID": 4335, "Title": "ROCHE-WO20697", "Description": "A randomized, open label study to compare the complete pathological response rate achieved with 4 combinations of Herceptin, docetaxel and pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer" },{ "PostingID": 14471, "Title": "ROCHE-BO22280", "Description": "A randomized study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy, as neoadjuvant therapy for patients with HER2-positive breast cancer." }]

Statistical Analysis Plan